Topical corticosteroids and bullous pemphigoid [3]

Archives of Dermatology

Volumn 139, Issue 2, 2003, Pages 225-226

  Hull, Christopher M ^b   McKenna, Jeffrey K ^b   Zone, John J ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; IMMUNOGLOBULIN A; TACROLIMUS;

BULLOUS SKIN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; HOSPITALIZATION; HUMAN; LETTER; MORTALITY; PEMPHIGOID; PRIORITY JOURNAL; STEROID THERAPY; STRIA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; DRUG ERUPTIONS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; PEMPHIGOID, BULLOUS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0037321669     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.2.225-a     Document Type: Letter

References (2)

1. Williams L. Nesbitt L. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin. 2001;19:63-77.
2. Joly P, Roujeau JC, Picard C, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321-327.